ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021
Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.Journal of global health · 2023Pooled it
- Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.International journal of dermatology · 2022Pooled it
- Cutaneous adverse reactions following COVID-19 vaccinations: A systematic review and meta-analysis.Journal of cosmetic dermatology · 2022Pooled it
- Short-term side effects of COVID-19 vaccines among healthcare workers: a multicenter study in Iran.Scientific reports · 2024Article
- Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review.Tanaffos · 2024Review
- Article
- COVID-19 Vaccine Hesitancy Among Pregnant Women.Cureus · 2023Article
- Does ChAdOx1-S and BNT162b2 heterologous prime-boost vaccination trigger higher rates of vaccine-related adverse events?IJID regions · 2023Article
- Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system.BMC infectious diseases · 2023Article
- A First Report on Side-Effects of COVID-19 Vaccines among General Population in Sudan: A Cross-Sectional Analysis.Vaccines · 2023Article
- Article
- Immune interference in effectiveness of influenza and COVID-19 vaccination.Frontiers in immunology · 2023Review
- Exploring interrelationships of COVID-19 dimensions in Saudi Arabia: a systematic review.Bulletin of the National Research Centre · 2023Review
- Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study.Frontiers in public health · 2023Article
- Side effects of COVID-19 vaccines in the middle eastern population.Frontiers in immunology · 2023Review
- Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.Frontiers in immunology · 2023Review
- Adverse Events of COVID-19 Vaccination among the Saudi Population: A Systematic Review and Meta-Analysis.Vaccines · 2022Review
- Surveillance of Side Effects after Two Doses of COVID-19 Vaccines among Patients with Comorbid Conditions: A Sub-Cohort Analysis from Saudi Arabia.Medicina (Kaunas, Lithuania) · 2022Article
- Side effects of COVID-19 vaccines and perceptions about COVID-19 and its vaccines in Bangladesh: A Cross-sectional study.Vaccine: X · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults.
methodsThis cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose.
resultsOf the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations.
conclusionThis study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.